Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort StudyLene Sofie Granfeldt Østgård, Bruno C Medeiros, Henrik Sengeløv, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 21, 2017
Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort StudyLene Sofie Granfeldt Østgård, Jennifer L Lund, Jan Maxwell Nørgaard, et al.
Blood Advances|December 21, 2021
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndromeAaron T Gerds, Bart L Scott, Peter Greenberg, et al.
Leukemia & Lymphoma|February 28, 2007
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years)Bruno C Medeiros, Mark D Minden, Andre C Schuh, et al.
Leukemia Research|September 22, 2019
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemiaDaniel J DeAngelo, Alison R Walker, Richard F Schlenk, et al.
Scientific Reports|September 17, 2016
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein ResponseDadi Jiang, Connor Lynch, Bruno C Medeiros, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
British Journal of Haematology|March 4, 2015
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 studyRonan T Swords, Harry P Erba, Daniel J DeAngelo, et al.
Blood|May 27, 2014
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patientsArthur E Frankel, Jung H Woo, Chul Ahn, et al.
Cell Reports|March 30, 2017
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid LeukemiaAlyssa Carey, David K Edwards, Christopher A Eide, et al.
Pageof 11